European advances in digital rheumatology: explainable insights and personalized digital health tools for psoriatic arthritis.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 40496877.
- Also identified by DOI 10.1016/j.eclinm.2025.103243 and PMC identifier 12146546.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The shift from traditional to technology-based diagnosis and management of psoriatic arthritis (PsA) represents a significant evolution in patient care. Traditionally, PsA was diagnosed and managed through clinical evaluations, physical examinations, and basic imaging techniques. With the evolution of digital technologies, the PsA care is transforming, giving rise to the field of digital rheumatology. In this vein, Europe has invested in research initiatives, like iPROLEPSIS, that could accelerate this transformation and redefine PsA care within a digital world. In this <i>Viewpoint</i> we present the current clinical PsA landscape, highlight the PsA patients' interaction with the digital world, and showcase the novel iPROLEPSIS digital offerings. The latter scaffold digital rheumatology by identifying PsA key drivers. Moreover, they support personalized PsA risk prediction and improve early PsA detection. Furthermore, they enable precise PsA treatment strategies and digital therapeutics within a novel digital health ecosystem.